Increasing Cancer Epidemic Driving Growth In The Oligonucleotide Therapy Market: The Driving Engine Behind Oligonucleotide Therapy Market Evolution in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Oligonucleotide Therapy Market Size Growth Forecast: What to Expect by 2025?
The market size for oligonucleotide therapy has been swiftly expanding in the past few years. Projected growth is from $5.61 billion in 2024 to $6.2 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.5%. The increase during the historic phase could be linked to increased investment in research and development, the emergence of initial therapies, the ascendance of gene editing techniques, early treatment discoveries and the introduction of RNAi and antisense oligonucleotide.

How Will the Oligonucleotide Therapy Market Size Evolve and Grow by 2029?
In the years to come, the oligonucleotide therapy market is projected to experience swift expansion. The market size is predicted to reach "$9.66 billion in 2029 with a compound annual growth rate (CAGR) of 11.8%. The anticipated growth in this period is credited to investment in research and development, increased global market penetration, expansion of the therapeutic area, implementation of disease modification strategies, and regulatory adaptations. Key trends projected throughout this period include the development of personalized therapies, advancements in delivery systems, the progression of RNA interference (RNAI), innovation in antisense oligonucleotide, as well as the incorporation of gene editing techniques.

View the full report here:
https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

What Drivers Are Propelling the Growth of Oligonucleotide Therapy Market Forward?
The escalating incidences of cancer worldwide is anticipated to bolster the expansion of the oligonucleotide therapy market in the forecast period. For example, the American Cancer Society speculated in January 2022 that the US is likely to observe 1.9 million fresh cancer diagnoses and 609,360 deaths linked to cancer, roughly 1,670 casualties daily. The four most prevalent cancer types globally - lung, prostate, bowel, and female breast cancer - represent 43% of all new cancer diagnoses. Hence, the increasing rate of cancer globally predicts an upswing in demand for oligonucleotide therapy in the ensuing years.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3398&type=smp

What Are the Key Trends Driving Oligonucleotide Therapy Market Growth?
The market entities involved in the oligonucleotide therapy arena are channelling their resources into research and development to modify the therapy design and decrease its negative impact on patients. The cutting-edge oligonucleotides open avenues for precision medicine methodologies and can be engineered to selectively interact with any gene while causing minimal side-effects. It is also beneficial in zeroing in on specific sequences in patients that lead to rare diseases. In April 2023, Qalsody, an antisense oligonucleotide (ASO), gained FDA approval for usage in treating patients affected with amyotrophic lateral sclerosis (ALS) related to a mutation in the superoxide dismutase 1 (SOD1) gene. SOD1 mRNA is the target of Qalsody to curb the SOD1 protein synthesis.

What Are the Key Segments in the Oligonucleotide Therapy Market?
The oligonucleotide therapy market covered in this report is segmented -

1) By Type: Antisense Oligonucleotide, Aptamer, Other Types
2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User
3) By End User: Hospitals, Research Institutes

Subsegments:
1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides, DNA-Targeted Antisense Oligonucleotides, Chemically Modified Antisense Oligonucleotides
2) By Aptamer: DNA Aptamers, RNA Aptamers, Small Molecule Aptamers
3) By Other Types: siRNA (Small Interfering RNA), miRNA (Micro RNA), DNAzyme And Ribozymes, Synthetic Oligonucleotides For Gene Editing

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3398&type=smp

Who Are the Key Players Shaping the Oligonucleotide Therapy Market's Competitive Landscape?
Major companies operating in the oligonucleotide therapy market include Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Gilead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Jazz Pharmaceuticals plc, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., PepGen Ltd.

What Geographic Markets Are Powering Growth in the Oligonucleotide Therapy Market?
North America was the largest region in the oligonucleotide therapy market in 2024. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3398

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email:saumyas@tbrc.info
The Business Research Company -www.thebusinessresearchcompany.com
Follow Us On:
LinkedIn:https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.